drugset / Trial / NCT04072432
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
Non-randomizedSequentialOpen-labelPrevention
Summary
This is a Phase 1b, single center, dose-escalating study evaluating the safety, tolerability, and pharmacodynamic effect of RBT-3 in healthy volunteers and in subjects with stage 3-4 chronic kidney disease.
Timeline
- Start
- 2018-10-21
- Primary completion
- 2019-03-31
- Completion
- 2019-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RBT-3 | Unknown | 120 mg | Intravenous |
| Subject | RBT-3 | Unknown | 240 mg | Intravenous |
| Subject | RBT-3 | Unknown | 360 mg | Intravenous |